Immunotherapy: Gut bacteria modulate responses to PD-1 blockade.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.Oncoimmunology · 2026
   Review
2. The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.Cancer immunology, immunotherapy : CII · 2026
   Review
3. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.Journal of clinical medicine · 2026
   Article
4. Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting.Cancer biome and targeted therapy · 2026
   Article
5. Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.Molecular cancer · 2025
   Review
6. Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
   Review
7. Role of Gut Microbiota in Breast Cancer and Drug Resistance.Pathogens (Basel, Switzerland) · 2023
   Review
8. Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.Frontiers in pharmacology · 2023
   Review
9. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.Gut · 2022
   Review
10. Urobiome in Gender-Related Diversities of Bladder Cancer.International journal of molecular sciences · 2020
    Review
11. Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.Trends in cancer · 2018
    Review

Corrections and comments

• Comment on
  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.2018
• Comment on
  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as